Kyntra Bio Inc(KYNB) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 21 at 4:00 PM ET (Korea 10/22 05:00)
Full metrics table
| Index | - | P/E | 0.16 | EPS (ttm) | 32.31 | Insider Own | 7.21% | Shs Outstand | 4.0M | Perf Week | -6.38% |
| Market Cap | 0.02B | Forward P/E | - | EPS next Y | -13.78% | Insider Trans | - | Shs Float | 3.8M | Perf Month | -28.43% |
| Enterprise Value | -0.05B | PEG | - | EPS next Q | -3.55 | Inst Own | 24.67% | Short Float | 2.66% | Perf Quarter | -26.31% |
| Income | 0.13B | P/S | 4.57 | EPS this Y | -119.09% | Inst Trans | -1.02% | Short Ratio | 5.12 | Perf Half Y | -27.54% |
| Sales | 0.00B | P/B | - | EPS next 5Y | - | ROA | -22.15% | Short Interest | 0.10M | Perf YTD | -40.66% |
| Book/sh | -7.44 | P/C | 0.23 | EPS past 3/5Y | - | ROE | - | 52W High | -55.28% ($11.65) | Perf Year | -53.27% |
| Cash/sh | 22.55 | P/FCF | - | Sales past 3/5Y | -64.23% -48.42% | ROIC | - | 52W Low | 7.42% ($4.85) | Perf 3Y | -62.1% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | 6280.6% | Gross Margin | 1.65% | Volatility(W/M) | 7.72% 5.82% | Perf 5Y | -98.03% |
| Dividend TTM | - | EV/Sales | -10.44 | Sales Y/Y TTM | -91.38% | Oper. Margin | -1088.33% | ATR (14) | 0.37 | Perf 10Y | -98.8% |
| Dividend Ex-Date | - | Quick Ratio | 2.59 | EPS Q/Q | 257.26% | Profit Margin | 2830.95% | RSI (14) | 28.94 | Recom | 1.33 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.69 | Sales Q/Q | -209.35% | SMA20 | -13.8% ($6.04) | Beta | 1.04 | Target Price | $36.8 |
| Payout | - | Debt/Eq | - | Earnings | 2026/8/13 | SMA50 | -25.76% ($7.02) | Rel Volume | 0.6 | Prev Close | $5.28 |
| Employees | 34 | LT Debt/Eq | - | EPS/Sales Surpr. | 192.96% -171.78% | SMA200 | -28.28% ($7.26) | Avg Volume(3M) | 0.02M | Price | $5.21 |
| IPO | 2014/11/14 | Option/Short | No/Yes | Trades | 196 | Volume | 11,802 | Change | -1.33% |
🧬 Kintra Bio is a US biopharmaceutical company formed when the former FibroGen changed its name and ticker symbol in January 2026. The company focuses on oncology and anemia, with key pipelines including <strong>FG-3246</strong>, a CD46-targeting ADC aimed at metastatic castration-resistant prostate cancer (mCRPC), and <strong>roxadustat</strong>, which is being developed for chronic kidney disease and lower-risk MDS. Listed on Nasdaq as a small-cap stock, Kintra Bio is pursuing a focused strategy after securing cash through the sale of its Chinese subsidiary.
Over the past 1 year, on the lower side
55% below its 1-year high.
Traded less than usual. That is 60% of its average volume.
KYNB has a sound balance sheet but weak earning power
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -119.1% this year.
Tap to view numbers
Within its industry, it looks cheap
For a company earning $100 a year, you would pay $16. Peers typically go for $1,446. Compared with its own 1-year average, it is 50% cheaper now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -98.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership is about average
Institutions hold 24.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
VTI Vanguard Morningstar Total Stock Market ETF <0.01% 
VXF Vanguard Extended Market Index ETF <0.01% It ranks #464 of 595 in the industry
Based on market cap of $21M.
MCRB#462 Seres Therapeutics Inc $23M PER - 
PLRZ#463 Polyrizon Ltd $21M PER - KYNB#464 Kyntra Bio Inc $21M PER 0.2 
CNTX#465 Context Therapeutics Inc $21M PER - 
BYSI#466 BeyondSpring Inc $20M PER - 
FAQ
What kind of company is KYNB?
KYNB belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of KYNB?
The market cap of KYNB is approximately $21M, ranking 5,208 within its sector.
What is the P/E ratio of KYNB?
KYNB has a P/E ratio of approximately 0.2x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KYNB?
KYNB has recorded a 52-week high of $11.65 and a low of $4.85.
